Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230125 · ClinicalTrials.gov registry record · Phase 3
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
A Phase 3 study of Cataract, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
- 1
- Study location
NCT01230125 is a Phase 3 study of Cataract that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 311 participants, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01230125, a Phase 3 study of Cataract, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Mapracorat
Study Locations (1)
New York
- Bausch & Lomb, Incorporated - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230125
The ClinicalTrials.gov registry entry for NCT01230125 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (38% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT01230125 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01230125 about?
NCT01230125 is a clinical study titled "Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery". The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
What is the current status of trial NCT01230125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2010-11. Estimated completion is 2011-08.
What conditions does trial NCT01230125 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT01230125?
The interventions under investigation include: Vehicle (DRUG), Mapracorat (DRUG).
Who is sponsoring clinical trial NCT01230125?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01230125 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
Study of T-PRED(TM) Compared to Pred Forte(R) II
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.